{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:55Z","timestamp":1788866935083,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.diabres.2024.111839","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T00:02:09Z","timestamp":1724544129000},"page":"111839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice"],"prefix":"10.1016","volume":"216","author":[{"given":"I.","family":"Aguilera Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Garc\u00eda Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"L\u00f3pez Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Barquiel Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"V\u00e1zquez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Barreda Bonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zamarr\u00f3n de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Palma Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Prados S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gonz\u00e1lez P\u00e9rez de Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diabres.2024.111839_b0005","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.diabres.2024.111839_b0010","first-page":"1","article-title":"Cystic fibrosis-related diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.diabres.2024.111839_b0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcf.2019.03.010","article-title":"Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis","volume":"18","author":"Prentice","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabres.2024.111839_b0020","doi-asserted-by":"crossref","unstructured":"Grasemann H, Ratjen F. Cystic Fibrosis. Taichman DB, editor. New England Journal of Medicine [Internet]. 2023 Nov 2;389(18):1693\u2013707. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra2216474.","DOI":"10.1056\/NEJMra2216474"},{"issue":"17","key":"10.1016\/j.diabres.2024.111839_b0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del Alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.diabres.2024.111839_b0030","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.diabres.2024.111839_b0035","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.diabres.2024.111839_b0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabres.2024.111839_b0045","first-page":"30","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"1","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.diabres.2024.111839_b0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.diabres.2024.111839_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2024.111839_b0060","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.diabres.2024.111839_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor \/ tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2024.111839_b0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabres.2024.111839_b0075","first-page":"33","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"1","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"58","key":"10.1016\/j.diabres.2024.111839_b0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clnesp.2023.08.028","article-title":"Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","volume":"1","author":"Taelman","year":"2023","journal-title":"Clin Nutr ESPEN"},{"issue":"10","key":"10.1016\/j.diabres.2024.111839_b0085","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1210\/jc.2018-02763","article-title":"Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study","volume":"104","author":"Shah","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2024.111839_b0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"10","key":"10.1016\/j.diabres.2024.111839_b0095","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.2337\/dci21-0034","article-title":"Consensus report: Definition and interpretation of remission in type 2 diabetes","volume":"44","author":"Riddle","year":"2021","journal-title":"Diabetes Care"},{"issue":"S48","key":"10.1016\/j.diabres.2024.111839_b0100","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/ppul.23762","article-title":"CF-related diabetes: containing the metabolic miscreant of cystic fibrosis","volume":"52","author":"Moheet","year":"2017","journal-title":"Pediatric pulmonology"},{"key":"10.1016\/j.diabres.2024.111839_b0105","unstructured":"Cystic Fibrosis Foundation. Patient Registry Annual Data Report (2023). Bethesda, Maryland: Cystic Fibrosis Foundation."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T08:53:06Z","timestamp":1726217586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724007496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":21,"alternative-id":["S0168822724007496"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111839","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111839"}}